Can local institutions reduce poverty? Rural decentralization in Burkina Faso

The authors present evidence that in Burkina Faso, certain high-performing local institutions contribute to equitable economic development. They link reduced levels of poverty, and inequality to a high degree of internal village organization. The structure of these high-performing local organizations means they can exist in a number of African countries, because they depend more on internal participation, rather than on nay one country's cultural assets. The authors find that: 1) Service-asset management groups (SAMs) - one of three local institutions identified in the study - have helped to significantly reduce inequality in participating households. SAMs are a fusion of long-standing development committees, and indigenous management councils that collectively manage community assets, such as water. SAMs have combined the productivity goals of growth, with the values of equity, and solidarity. 2) Current development approaches use growth as an initiator, assuming that surpluses will be used to benefit the poor. SAMs, and other local institutions in Burkina Faso, start with equity, and solidarity, and aim for a result of growth, and development. 3) Internal participation is essential for SAMs to function. Only locally anchored participation can power the realignments, and institutional revisions needed to scale up development action. SAMs, and other local institutions have launched their communities on equitable growth paths, and are reducing poverty with little, or no outside assistance, despite severe resource constraints. Their impact could be enormous if external development resources augmented their potential. World Bank programs, and policy interventions could build on local strength, and make their activities more sustainable by mapping local institutions to guide new initiatives in pro-poor investment, and using that mapping to formalize, and increase internal local participation - expanding nationwide by using a network of local institutions. SAMs, and other local institutions, could be the vehicle for ensuring transparency, and accountability. Working with the results of local activities, national policies could favor the development of indigenously based, but externally oriented local economies.Decentralization,Regional Rural Development,Public Health Promotion,Enterprise Development&Reform,Economic Theory&Research,Regional Rural Development,Health Economics&Finance,Poverty Assessment,Governance Indicators,National Governance

Assessing the competitive ability of the invader Senna obtusifolia with coexisting natives species under different water stress regimes

Invasive species tend to pose a threat to ecosystem biodiversity, functioning, and ecosystem service provision. This study was conducted in Burkina Faso to assess the competitiveness of an invasive species Senna obtusifolia that is a less palatable legume plant in West African Sahelian rangelands. To address the research hypothesis that the recurrent drought in the Sahel results in S. obtusifolia being more competitive in the land invasion, we conducted an interspecific competition involving S. obtusifolia and 3 herbaceous species (Andropogon gayanus, Chamaecrista mimosoides, and Pennisetum pedicellatum) in a greenhouse experiment under four water stress regimes using a replacement series design. The height and biomass of each species were measured throughout four months experiment. In the severe water regime, S. obtusifolia was the most sensitive to water deficit while the 3 other species were found to be resistant. In addition, in all water regimes, the aggressivity index revealed that S. obtusifolia was less competitive than the grass species A. gayanus and P. pedicellatum. Further, the study discovered that drought in the Sahel made S. obtusifolia more vulnerable than the other species. Hence the invasion of Sahelian rangelands by S. obtusifolia could be favored by overgrazing that reduces fodder species' dominance and competitiveness. Good management of sahelian rangelands by controlling grazing could help to reduce S. obtusifolia invasion and provide more fodder for livestock

Analyse des structures syntaxiques des kisgu « interdits sociaux » chez les Moose de Sabcé

Résumé : Les interdits sociaux chez les Moose de Sabcé sont des règles de conduite qui encadrent la vie de la communauté moaaga de cette localité du Burkina Faso. Si ces interdits sont présents et bien connus dans toute la communauté, la maîtrise de leurs structures reste moins connue. C’est la raison pour laquelle nous avons choisi d’analyser les structures syntaxiques des interdits sociaux des Mosse de Sabcé. L’objectif de cette étude est de répertorier les différents types d’interdits afin de dégager les structures syntaxiques des énoncés de ces formules langagières moose. Pour ce faire, le structuralisme à visée fonctionnaliste de Maurice HOUIS (1963 et1971) et de Denis CREISSELS (1991, 2006a et b) nous a permis de mener à bien l’analyse. Après analyse, nous sommes arrivés aux résultats que les différents types de phrases rencontrés dans la formulation des énoncés des interdits sociaux sont des phrases de type déclaratif. Aussi, les structures syntaxiques des énoncés des interdits sociaux sont : des phrases simple et composé. Mots-clés : structures syntaxiques, formule langagière, interdits sociaux, Moose, Sabc

Multiparity and Breast Cancer Risk Factor among Women in Burkina Faso

The relative lack of information on breast cancer etiology in Burkina Faso led us to undertake the present work to highlight risk factors. This prospective study was conducted using a questionnaire between January 2015 and February 2016 on women admitted to Yalgado OUEDRAOGO hospital, for consultation or supervision. The characteristics of multiparous breast cancer patients (n = 44) were compared with their non-multiparous counterparts (n = 36). The study found that increased risk of breast cancer among non-multiparous cases was related to body mass index (BMI) (p <0.001), age at menopause (p <0.004) and use of oral contraception (p <0.021) while abortion (p <0.002) was a risk factor among multiparous cases. These results suggest that even if multiparity is associated with a decreased risk in some women, avoidance of abortion during reproductive life should be recommended. The results provide preliminary information, which now need to be supplemented by survey of a larger sample in the national territory.Peer reviewe

Enabling environment for circular bioeconomy sector in Burkina Faso

Circular bioconomy (CBE) have emerged as effective tools for triggering a sustainable development process consequent to the fear of cascading risks, growing instability in the world market and the recent Coronavirus disease 19 (COVID-19) pandemic. Promoting the development of business models towards CBE can help countries meet the Sustainable Development Goals (SDGs) and the needs of growing population while supporting vulnerable and marginalized groups (Schroder et al., 2018, Rodriguez- Anton et al., 2022). Burkina Faso has a huge opportunity and natural resources to develop CBE. In the country, the agricultural sector employs 63% of the employed workforce and contributes to 16% of the Gross Domestic. National statistics indicate that in 2021 the largest national productions were maize (1,853,509 tons), followed by sorghum (1,643,721 tons); millet (705,344 ton); cowpea (704,539 tons); cotton (696,635 tons, including fiber and seeds) and peanuts (630,525 tons) (INSD – EPA, 2021-2022)

Genomic Epidemiology of SARS-CoV-2 in Western Burkina Faso, West Africa.

BACKGROUND: After its initial detection in Wuhan, China, in December 2019, SARS-CoV-2 has spread rapidly, causing successive epidemic waves worldwide. This study aims to provide a genomic epidemiology of SARS-CoV-2 in Burkina Faso. METHODS: Three hundred and seventy-seven SARS-CoV-2 genomes obtained from PCR-positive nasopharyngeal samples (PCR cycle threshold score &lt; 35) collected between 5 May 2020, and 31 January 2022 were analyzed. Genomic sequences were assigned to phylogenetic clades using NextClade and to Pango lineages using pangolin. Phylogenetic and phylogeographic analyses were performed to determine the geographical sources and time of virus introduction in Burkina Faso. RESULTS: The analyzed SARS-CoV-2 genomes can be assigned to 10 phylogenetic clades and 27 Pango lineages already described worldwide. Our analyses revealed the important role of cross-border human mobility in the successive SARS-CoV-2 introductions in Burkina Faso from neighboring countries. CONCLUSIONS: This study provides additional insights into the genomic epidemiology of SARS-CoV-2 in West Africa. It highlights the importance of land travel in the spread of the virus and the need to rapidly implement preventive policies. Regional cross-border collaborations and the adherence of the general population to government policies are key to prevent new epidemic waves

Prevention of mother-to-child transmission of hepatitis B virus in Burkina Faso: Screening, vaccination and evaluation of post-vaccination antibodies against hepatitis B surface antigen in newborns

The low rate of screening for hepatitis B virus (HBV) in pregnant women is a highrisk factor for its vertical transmission. The objectives of this study were: i) to screen pregnant women for HBV infection; ii) vaccinate all children from birth against HBV regardless their mother HBV status; and iii) evaluate after 7 months of birth the level of their AbHBs among babies who received HBV vaccine at birth. Serological markers of HBV (HBsAg, HBeAg, AbHBs, AbHBe, and AbHBc) were determined on venous blood samples from 237 pregnant women and their children using the Abon Biopharm Kit. One hundred and two (102) children received the three doses of the EUVAX B® vaccine respectively at birth, two months and four months of life. Seven months after delivery, venous blood samples were collected from mothers and their children. Antibodies against hepatitis B surface antigen (AbHBs) were measured in vaccinated children using the ELISA Kit AbHBs Quantitative EIA. DNA extraction was performed on samples from HBV-seropositive mothers and their children using the Ribo Virus (HBV Real-TM Qual) Kit and for Real Time PCR, the HBV Real-TM Qual Kit was used. Serological diagnosis in pregnant women revealed 22 (9.28%) hepatitis B surface antigen (HBsAg) positive samples of which 21 were positive for viral DNA by real-time PCR. Among the 22 HBsAg+ women, five (05) transmitted the virus to their children with a vertical transmission rate of 22.73%. A transmission rate of 23.81% (5/21) was found with the PCR method. Analysis of AbHBs levels revealed that 98.31% of the children had an average concentration of 218.07 ± 74.66 IU/L, which is well above the minimum threshold for protection (11 IU/L). This study has confirmed that vertical transmission of HBV is a reality in Burkina Faso and that vaccination at birth would significantly reduce this transmission

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

BACKGROUND: Malaria is a leading cause of morbidity and mortality worldwide. We previously reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified goal of 75% or greater efficacy over 12 months in the target population of African children. Here, we report the safety, immunogenicity, and efficacy results at 12 months following administration of a booster vaccination. METHODS: This double-blind phase 1/2b randomised controlled trial was done in children aged 5-17 months in Nanoro, Burkina Faso. Eligible children were enrolled and randomly assigned (1:1:1) to receive three vaccinations of either 5 μg R21/25 μg Matrix-M, 5 μg R21/50 μg Matrix-M, or a control vaccine (the Rabivax-S rabies vaccine) before the malaria season, with a booster dose 12 months later. Children were eligible for inclusion if written informed consent could be provided by a parent or guardian. Exclusion criteria included any existing clinically significant comorbidity or receipt of other investigational products. A random allocation list was generated by an independent statistician by use of block randomisation with variable block sizes. A research assistant from the University of Oxford, independent of the trial team, prepared sealed envelopes using this list, which was then provided to the study pharmacists to assign participants. All vaccines were prepared by the study pharmacists by use of the same type of syringe, and the contents were covered with an opaque label. Vaccine safety, efficacy, and a potential correlate of efficacy with immunogenicity, measured as anti-NANP antibody titres, were evaluated over 1 year following the first booster vaccination. The population in which the efficacy analyses were done comprised all participants who received the primary series of vaccinations and a booster vaccination. Participants were excluded from the efficacy analysis if they withdrew from the trial within the first 2 weeks of receiving the booster vaccine. This trial is registered with ClinicalTrials.gov (NCT03896724), and is continuing for a further 2 years to assess both the potential value of additional booster vaccine doses and longer-term safety. FINDINGS: Between June 2, and July 2, 2020, 409 children returned to receive a booster vaccine. Each child received the same vaccination for the booster as they received in the primary series of vaccinations; 132 participants received 5 μg R21 adjuvanted with 25 μg Matrix-M, 137 received 5 μg R21 adjuvanted with 50 μg Matrix-M, and 140 received the control vaccine. R21/Matrix-M had a favourable safety profile and was well tolerated. Vaccine efficacy remained high in the high adjuvant dose (50 μg) group, similar to previous findings at 1 year after the primary series of vaccinations. Following the booster vaccination, 67 (51%) of 132 children who received R21/Matrix-M with low-dose adjuvant, 54 (39%) of 137 children who received R21/Matrix-M with high-dose adjuvant, and 121 (86%) of 140 children who received the rabies vaccine developed clinical malaria by 12 months. Vaccine efficacy was 71% (95% CI 60 to 78) in the low-dose adjuvant group and 80% (72 to 85) in the high-dose adjuvant group. In the high-dose adjuvant group, vaccine efficacy against multiple episodes of malaria was 78% (95% CI 71 to 83), and 2285 (95% CI 1911 to 2568) cases of malaria were averted per 1000 child-years at risk among vaccinated children in the second year of follow-up. Among these participants, at 28 days following their last R21/Matrix-M vaccination, titres of malaria-specific anti-NANP antibodies correlated positively with protection against malaria in both the first year of follow-up (Spearman's ρ -0·32 [95% CI -0·45 to -0·19]; p=0·0001) and second year of follow-up (-0·20 [-0·34 to -0·06]; p=0·02). INTERPRETATION: A booster dose of R21/Matrix-M at 1 year following the primary three-dose regimen maintained high efficacy against first and multiple episodes of clinical malaria. Furthermore, the booster vaccine induced antibody concentrations that correlated with vaccine efficacy. The trial is ongoing to assess long-term follow-up of these participants and the value of further booster vaccinations. FUNDING: European and Developing Countries Clinical Trials Partnership 2 (EDCTP2), Wellcome Trust, and NIHR Oxford Biomedical Research Centre. TRANSLATION: For the French translation of the abstract see Supplementary Materials section

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

BACKGROUND: Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new candidate vaccine for safety and efficacy. METHODS: In this double-blind, randomised, controlled, phase 2b trial, the low-dose circumsporozoite protein-based vaccine R21, with two different doses of adjuvant Matrix-M (MM), was given to children aged 5-17 months in Nanoro, Burkina Faso-a highly seasonal malaria transmission setting. Three vaccinations were administered at 4-week intervals before the malaria season, with a fourth dose 1 year later. All vaccines were administered intramuscularly into the thigh. Group 1 received 5 μg R21 plus 25 μg MM, group 2 received 5 μg R21 plus 50 μg MM, and group 3, the control group, received rabies vaccinations. Children were randomly assigned (1:1:1) to groups 1-3. An independent statistician generated a random allocation list, using block randomisation with variable block sizes, which was used to assign participants. Participants, their families, and the local study team were all masked to group allocation. Only the pharmacists preparing the vaccine were unmasked to group allocation. Vaccine safety, immunogenicity, and efficacy were evaluated over 1 year. The primary objective assessed protective efficacy of R21 plus MM (R21/MM) from 14 days after the third vaccination to 6 months. Primary analyses of vaccine efficacy were based on a modified intention-to-treat population, which included all participants who received three vaccinations, allowing for inclusion of participants who received the wrong vaccine at any timepoint. This trial is registered with ClinicalTrials.gov, NCT03896724. FINDINGS: From May 7 to June 13, 2019, 498 children aged 5-17 months were screened, and 48 were excluded. 450 children were enrolled and received at least one vaccination. 150 children were allocated to group 1, 150 children were allocated to group 2, and 150 children were allocated to group 3. The final vaccination of the primary series was administered on Aug 7, 2019. R21/MM had a favourable safety profile and was well tolerated. The majority of adverse events were mild, with the most common event being fever. None of the seven serious adverse events were attributed to the vaccine. At the 6-month primary efficacy analysis, 43 (29%) of 146 participants in group 1, 38 (26%) of 146 participants in group 2, and 105 (71%) of 147 participants in group 3 developed clinical malaria. Vaccine efficacy was 74% (95% CI 63-82) in group 1 and 77% (67-84) in group 2 at 6 months. At 1 year, vaccine efficacy remained high, at 77% (67-84) in group 1. Participants vaccinated with R21/MM showed high titres of malaria-specific anti-Asn-Ala-Asn-Pro (NANP) antibodies 28 days after the third vaccination, which were almost doubled with the higher adjuvant dose. Titres waned but were boosted to levels similar to peak titres after the primary series of vaccinations after a fourth dose administered 1 year later. INTERPRETATION: R21/MM appears safe and very immunogenic in African children, and shows promising high-level efficacy. FUNDING: The European & Developing Countries Clinical Trials Partnership, Wellcome Trust, and National Institute for Health Research Oxford Biomedical Research Centre